BMJ  2006;333:353-354 (12 August), doi:10.1136/bmj.333.7563.353-b

Letter

Fluoroquinolone resistance in Salmonella Typhi

The first 150 words of the full text of this article appear below.

EDITOR—As Parry et al point out,^{1 2} appropriate laboratory methods are crucial in detecting clinically important quinolone resistance.

We highlight the emergence of strains of Salmonella enterica serovar Typhi (S Typhi) that show reduced susceptibility to the fluoroquinolones but are susceptible to nalidixic acid (minimum inhibitory concentration < 16 mg/l). In a review of all 692 isolates of S Typhi sent to the Laboratory for Enteric Pathogens at the Health Protection Agency in London between 2000 and 2003 we detected 49 isolates that were susceptible to nalidixic acid but had reduced susceptibility to fluoroquinolone (minimum inhibitory concentration 0.125-1.0 mg/l; table).³ When the country of acquisition was known, 18 of these isolates were from patients who had visited India; eight, Pakistan; four, Bangladesh; and one, Kenya.

View this table: [in this window] [in a new window]   S Typhi susceptible to nalidixic acid but with reduced fluoroquinolone susceptibility imported into England, Scotland, and Wales, 2000-3

 

Overall, of 271 isolates . . . [Full text of this article]

fiona@sanger.ac.uk, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA

Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA

Health Protection Agency, Centre for Infections, London NW9 5HT

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Female genital mutilation: whose problem, whose solution?: Psychological damage is immense

Janet Menage
BMJ 2006 333: 260. [Extract] [Full Text]

Current concepts in the diagnosis and treatment of typhoid fever

Zulfiqar A Bhutta
BMJ 2006 333: 78-82. [Extract] [Full Text] [PDF]